Plain-English translation of NCT06735287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a bladder-sparing approach for patients with large non-muscle-invasive bladder cancers. Instead of removing the bladder surgically, doctors will treat the cancer using a combination of chemotherapy (pirarubicin) and immunotherapy after an initial procedure to remove the visible tumor. The goal is to control the cancer while letting you keep your bladder and avoid major surgery.
Most large bladder cancers are currently treated by removing the entire bladder, which significantly impacts quality of life. This trial exists to see if newer medications given after an initial tumor removal procedure can be just as effective—allowing patients to keep their bladder and avoid this major surgery.
You likely qualify if…
You likely don't qualify if…
You would first have a procedure (TURBT) to remove the visible tumor. After that, you would receive chemotherapy and immunotherapy medications as planned by your care team. You would then receive regular bladder instillation treatments with mitomycin C (a local chemotherapy) and attend follow-up appointments to monitor how well the treatment is working. The trial will compare outcomes between patients treated with this bladder-sparing approach and those who choose surgery to remove the bladder.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China